Email this article 
Post a Comment RISK FACTORS FOR DEVELOPMENT OF HEALTH CARE-ASSOCIATED INFECTIONS IN PATIENTS OF ONCOGEMATOLOGY AND BONE MARROW TRANSPLANTATION UNITS
- Authors: Ryakhovskikh SA1, Lyubimova AV1
-
Affiliations:
- Северо-Западный государственный медицинский университет им. И.И. Мечникова
- Issue: Vol 34, No 4 (2017)
- Pages: 24-32
- Section: Articles
- URL: https://journal-vniispk.ru/PMJ/article/view/6971
- DOI: https://doi.org/10.17816/pmj34424-32
- ID: 6971
Cite item
Full Text
Abstract
Aim. To reveal the risk factors for the development of health care-associated infections (HCAI) in oncohematological units. One of the main problems of failure of treatment among oncohematological patients are infectious complications, first of all, associated with medical care. Materials and methods. The study “case-control” was carried out on the bases of three units of bone marrow transplantation and Research Institute of Pediatric Oncology, Hematology and Transplantation named after R.M. Gorbacheva. The study involved 102 patients, treated over the period from 01.12.14 to 30.11.15. The group “cases” included patients with HCAI. Health care-associated infections were detected using standard determination of a case for each of nosological forms; the group “control” - patients without HCAI, treated at the studied units during the same period. Each group joined 51 patients. Results. The common risk factors for all the considered types of infectious complications were duration of neutropenic fever for more than 3 days, polychemotherapeutic scheme “fludarabine+busulfan”, all schemes of polychemotherapy, including fludarabine. The greatest number of risk factors was detected for such severe and nosological HCAI forms as sepsis and pneumonia. Fludarabine is an independent risk factor for the development of HCAI, its influence is growing against the background of presence of another risk factors, such as neutropenic fever. Conclusions. Until now, fludarabine, as a factor, causing the development of severe forms of infectious complications was described only for patients with chronic lymphatic leukemia. It was revealed that this chemical is an independent risk factor for patients with acute leucosis as well.
Full Text
##article.viewOnOriginalSite##About the authors
S A Ryakhovskikh
Северо-Западный государственный медицинский университет им. И.И. Мечникова
Email: svetaryahovskih@list.ru
аспирант кафедры эпидемиологии, паразитологии и дезинфектологии 191015, г. Санкт-Петербург, Кирочная ул., 41, тел. 8 (812) 303-50-50
A V Lyubimova
Северо-Западный государственный медицинский университет им. И.И. Мечниковадоктор медицинских наук, профессор кафедры эпидемиологии, паразитологии и дезинфектологии 191015, г. Санкт-Петербург, Кирочная ул., 41, тел. 8 (812) 303-50-50
References
- Аллогенная родственная трансплантация костного мозга: клинический протокол оперативного и диагностического вмешательства / рекомендовано Экспертным советом РГП на ПХВ «Республиканский центр развития здравоохранения» Министерства здравоохранения и социального развития Республики Казахстан от 9 июля 2015 г., available at: http://doc-player.ru/28669188-Klinicheskiy-pro-tokol-diag-nostiki-i-lecheniya-ostryy-mieloblast-nyy-leykoz-u-vzroslyh.html.
- Гаплоидентичная трансплантация костного мозга: клинический протокол оперативного и диагностического вмешательства / рекомендовано Экспертным советом РГП на ПХВ «Республиканский центр развития здравоохранения» Министерства здравоохранения и социального развития Республики Казахстан от 9 июля 2015 г., available at: http://www.rcrz.kz/docs/clinic_protocol/ 2015/%D0%A2%D0%B5%D1%80%D0%B0%D0%%.
- Аллогенная неродственная трансплантация костного мозга: клинический протокол оперативного и диагностического вмешательства / рекомендовано Экспертным советом РГП на ПХВ «Республиканский центр развития здравоохранения» Министерства здравоохранения и социального развития Республики Казахстан от 9 июля 2015 г., available at: https://di-seases.medelement.com/disease/%D0%B0%D0%BB% D0%BB%D0BE%D0%B3%D0%B.
- Forcina A. Baldan R., Marasco V., Cichero P., Bondanza A., Noviello M., Piemontese S., Soliman C., Greco R., Lorentino F., Giglio F., Messina C., Carrabba M., Bernardi M., Peccatori J., Moro M., Biancardi A., Nizzero P., Scarpellini P., Cirillo D.M. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplantation 2016; 26. doi: 10.1038/bmt.2016.
- Garnica M. Nouér S.A., Pellegrino F.L., Moreira B.M., Maiolino A., Nucci M. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infectious Diseases 2013; 31: 356.
- Lukenbill J. Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leukemia Research 2013; 37 (9): 986-994.
- Mendes E.T. Dulley F., Basso M., Batista M.V., Coracin F., Guimarães T., Shikanai-Yasuda M.A., Levin A.S., Costa S.F. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. International Journal of Infectious Diseases 2012; 16 (6): 424-428.
- Oliveira A.L de Souza M., Carvalho-Dias V.M., Ruiz M.A., Silla L., Tanaka P.Y., Simões B.P., Trabasso P., Seber A., Lotfi C.J., Zanichelli M.A., Araujo V.R., Godoy C., Maiolino A., Urakawa P., Cunha C.A., de Souza C.A., Pasquini R., Nucci M. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplan-tation 2007; 39 (12): 775-781.
- Rima Moghnieh Nour Estaitieh, Anas Mugharbil, Tamima Jisr, Dania I. Abdallah, Fouad Ziade, Loubna Sinno, and Ahmad Ibrahim Third generation cephalosporin resistant Enterobac-teriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation w. Front Cell Infect Microbiol 2015, available at: https://doi.org/10.3389/fcimb.2015.00011.
- Seiter K. Mamorska-Dyga A. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clinical Interventions in Aging 2015; 10: 951-961.
- Zhu Q. Tan D.C., Samuel M., Chan E.S., Linn Y.C. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leukemia & Lymphoma 2004; 45 (11): 2239-2245.
Supplementary files
